SlideShare a Scribd company logo
QUINOLONES AND
FLOUROQUINOLONES
DR LINUS WAFULA,JKUAT.
JUNE 2021.
QUINOLONES AND FLOUROQUINOLONES
• Introduction
• A group of synthetic antibacterial agents mainly effective
against gram negative organisms
• Nalidixic acid first member introduced in 1964 for urinary and
GIT infections
• Synthetic fluorinated analogs of nalidixic acid: are
fluoroquinolones (FQs) with extended spectrum and systemic
effects in 1980s.
• FQs are BACTERICIDAL, act by interfering with DNA
replication. Since then many synthesized with useful spectrum.
8/24/2021 DR WAF JUNE 2021 2
Nalidixic acid
• The first quinolone, nalidixic acid, was isolated as a by-product
of the synthesis of chloroquine
• Less potent ,limited spectrum Active against gram negative
bacteria – E.coli, Proteus, Klebsiella, Enterobacter, Shigella
• Inhibits bacterial DNA gyrase, Bactericidal Resistance develops
rapidly
• Pharmacokinetics: Absorbed orally Metabolized in liver, highly
protein bound, excreted in urine, half life – 8 hrs.
• Concentration in urine is lethal to common urinary pathogens
(20 – 50 times that in plasma) Quinolones
8/24/2021 DR WAF JUNE 2021 3
• Nalidixic acid Adverse effects :
• GI upset, rashes Neurological toxicity (in children) – headache,
vertigo, drowsiness, visual disturbances, seizures
• Hemolysis in G6PD deficiency
• Indication:
• Urinary antiseptic
• Diarrhoea caused by E.coli, Proteus, Shigella, Salmonella
Ampicillin resistant Shigella enteritis (cont..,) Quinolones
8/24/2021 DR WAF JUNE 2021 4
QUINOLONES.
• 2 Quinolones are synthetic antimicrobials having a quinolone
structure. • Active against gram-ve bacteria, newer fluorinated
compounds also inhibit gram +ve bacteria.
• • First member was nalidixic acid introduced in 1960’s
• • Their usefulness is limited to urinary and GI tract infections
because of
• Low potency
• Modest blood and tissue levels
• Limited spectrum
• High frequency of bacterial resistance
8/24/2021 DR WAF JUNE 2021 5
8/24/2021 DR WAF JUNE 2021 6
MODE OF ACTION.
In gram negative bacteria – Inhibition of DNA gyrase enzyme
(Inhibit negative super coiling)
In gram positive bacteria – •Inhibition of Topoisomerase IV –
Inhibition of nicking and separation of daughter DNA strands after
DNA replication
•The malformed DNA is digested by Exoneucleases Mechanism
of Action
8/24/2021 DR WAF JUNE 2021 7
8/24/2021 DR WAF JUNE 2021 8
Mechanism of action.
• DNA- Enzyme- . The gyrase is composed of two A subunits
and two B subunits.
• The A subunits can cut one of double strands of the DNA
• .This is an ATP- dependent reaction. The energy is provided by
B units.
• . FQs are inhibitor of A subunits.
• Therefore, the action of gyrase is inhibited and DNA replication
or transcription is blocked as result of the death of bacteria.
8/24/2021 DR WAF JUNE 2021 9
8/24/2021 DR WAF JUNE 2021 10
Mechanism of Resistance to Quinolones
& FQ.
• Due to
• 1. a) One or more point mutations in the quinolone binding
region of the target enzyme
b) A change in the permeability of the organism
2. DNA gyrase is the primary target in E coli, with single-step
mutants exhibiting amino acid substitution in the A subunit of
gyrase
3.Topoisomerase Ⅳ is a secondary target in E coli that is
altered in mutants expressing higher levels of resistance.
8/24/2021 DR WAF JUNE 2021 11
4.In staphylococci and streptococci, the situation is reversed,
topoisomerase Ⅳ is the primary target, and gyrase is the
secondary target.
5.Resistance to one fluoroquinolone, particularly if of high level,
generally confers cross-resistance to all other members of this
class.
8/24/2021 DR WAF JUNE 2021 12
General features of FQs
• Rapidly bactericidal & high potency
• Long post antibiotic effect on pseudomonas &
enterobacteriaceae
Attain high levels in body fluids & tissues
• Diarrhea and antibiotic-associated colitis unusual
• Low frequency of mutational resistance
Active against many β-lactam & aminoglycoside resistant
bacteria
Less active at acidic pH
8/24/2021 DR WAF JUNE 2021 13
Classification of FQs First generation.
1. Introduced in 1980 with one fluoro substitution Norfloxacin
Ciprofloxacin Ofloxacin (only as ophthalmic in the United
States) Pefloxacin
2. Second-generation: In 1990s with additional fluoro & other
substitution extending antimicrobial spectrum to gram positive
bacteria ,anaerobes and longer half life.
3.Levofloxacin, Moxifloxacin, Gemifloxacin, Prulifloxacin,
Lomefloxacin, Sparfloxacin, Finafloxacin .
8/24/2021 DR WAF JUNE 2021 14
8/24/2021 DR WAF JUNE 2021 15
Pharmacokinetics of FQs:
• Prototype : Ciprofloxacin • Oral given, well absorbed, be impaired
by divalent cations, including those in antacid
• Distributed widely in body fluids and tissues but CSF & aqueous
levels are low
• Urinary & billiary concentrations are 10-50 fold higher than plasma
• Less active in acidic pH
• Pass placenta reach to the fetus,
• Biotransformation of the drugs in the liver
• Most eliminated by renal, either tubular secretion or glomerular
filtration.
8/24/2021 DR WAF JUNE 2021 16
Therapeutic applications of FQs.
• Fluoroquinolones are extensively used treating general
infection.
• a. Urinary tract infections, even when caused by multidrug-
resistant bacteria: cystitis, prostatitis,pyelonephritis.
• b. Intestinal and biliary tract infections
• c. skin and Soft tissue infections, infected skin ulcers and
burns.
• d. Bone, joint and intra-abdominal infections
• e. Respiratory tract infections: empyema, pneumonia, lung
abcess.
8/24/2021 DR WAF JUNE 2021 17
Uses
• Bacterial Meningitis
• Enteric fever, caused by Salmonelle spp
• Bacterial Diarrhoeal diseases caused by campylobacter, shigella
• Gonorrhea and chancroid
• Conjuctivitis
• Tuberculosis
8/24/2021 DR WAF JUNE 2021 18
CIPROFLOXACIN
• prototype): Highly effective against pseudomonas •
• Drug of choice for prophylaxis & treatment of Anthrax & prophylaxis
of meningococcal meningitis.
• Typhoid
• UTIs • Bacterial gastroenteritis • Osteomyelitis & joint infections •
Gonorrhea & chanchroid • Septicemia due to gram negative
organisms •
• Respiratory infections especially due to Mycoplasma, H. influenza,
Legionella • Prophylaxis of infections in neutropenic & cancer
patients •
• Topical use: conjunctivitis Unique features of different FQs.
8/24/2021 DR WAF JUNE 2021 19
NORFLOXACIN
• Minimum oral bioavailability •
• Minimum Inhibitory concentration for gram negative bacteria is
8-10 times higher than that of ciprofloxacin.
• Attains lower concentration in tissues
Less potent than ciprofloxacin
Primarily used in urinary & genital tract infections
For bacterial diarrheas it is good as anaerobic flora of the gut not
affected. Unique features of different FQs.
8/24/2021 DR WAF JUNE 2021 20
Unique features of different FQs
PEFLOXACIN:
• Methyl derivative of Norfloxacin
Completely absorbed, exhibits cumulation on repeated absorbtion
• More lipid soluble, CSF concentration are higher than other FQs •
Highly metabolized in liver to active metabolite
• Dose needs to be reduced in liver disease but not in renal
insufficiency
• Preferred for meningeal infections
• 200,400mg tablet available & injection 400mg/5ml to be used diluted
in glucose solution but not in saline as it precipitates in presence of
Chloride ions.
8/24/2021 DR WAF JUNE 2021 21
Unique features of different FQs
OFLOXACIN:
• Lipid soluble oral bioavailability is high
• Food does not interfere its absorption
Oral tablet (200 & 400mg) & i.v.(200mg)
Largely excreted unchanged by kidney ,so dose need reduced in
renal failure
Effective for gonococcal infection, including disseminated disease.
• Occasionally used for treatment of tuberculosis and atypical
mycobacterial infections
• Suitable for eradication of meningococcal infections from carriers.
• Highly effective in: leprosy, Chlamydial urethritis or cervicitis ,
atypical (Mycoplasma) pneumonia & Chronic bronchitis (cont..,)
8/24/2021 DR WAF JUNE 2021 22
SPARFLOXACIN.
• Excreted by both renal & hepatic Long half life
• Increased action against gram positive bacteria, Streptococcus,
Staphylococcus, Enterococcus,Anaerobes & mycobacteria
• NOT effective against Peudomonas
• Indication: upper and lower respiratory tract infections. Highly
effective in Tuberculosis, , Macobacterium Avium Complex,
Leprosy
• Adverse effects: Phototoxic QT prolongation (cont..,)
8/24/2021 DR WAF JUNE 2021 23
MOXIFLOXACIN
• Hepatic metabolism & biliary excretion Tablet & intravenous
(400 mg) Indications: MDR tuberculosis, Bronchitis, pneumonia,
otitis media, Urinary concentrations are low not suitable for UTI
• Contraindications : Primarily metabolised in liver, not used in
liver disease Patients with Seizures & Patients receiving
proarrythmic drugs as it prolong Q-T interval.
8/24/2021 DR WAF JUNE 2021 24
LEVOFLOXACIN:
• L-isomer of ofloxacin
• Maximum oral bioavailablity, given orally or i.v.
• Excreted unchanged by kidney Indications :
• Upper and lower respiratory tract infections. Community
acquired pneumonia :
• (Respiratory FQ) MDR TB, nosocomial infections Eye drops for
bacterial conjunctivitis & corneal ulcer. (cont..,)
8/24/2021 DR WAF JUNE 2021 25
LOMEFLOXACIN
• Similar to Ciprofloxacin ,more active against Gram negative
bacilli & chlamydia Longer plasma half life ,once daily
administration 400 mg tablet available & Topical eye drops
available (0.3%) Side effect:
• Photo toxicity & Q-T prolongation Withdrawn in USA & other
countries, available in India (cont..,)
8/24/2021 DR WAF JUNE 2021 26
8/24/2021 DR WAF JUNE 2021 27
WITHDRAWN FROM THE MARKET
• Due to adverse effects like
• Gatifloxacin: QT prolongation & dysglycemia (increase or
decrease blood sugar level: risky in diabetics) withdrawn from
market.
• Temafloxacin: immune hemolytic anemia
• Grepafloxacin: cardiotoxicity: QT prolongation
• Clinafloxacin : phototoxicity
8/24/2021 DR WAF JUNE 2021 28
SIDE EFFECTS.
• The most common effects are
• a) nausea, vomiting, and diarrhea.
• b) Headache, dizziness, insomnia, skin rash, occasionally.
• c). Photosensitivity occurs with lomefloxacin and pefloxacin.
• d). FQs may damage growing cartilage and cause an arthropathy.
• They are not used in patients under 18years of age.
• The arthropathy is reversible.
• e) FDA has issued warning regarding peripheral neuropathy
• f) Ciprofloxacin prophylaxis use in anthrax patients associated with
damage to muscle ligament.
8/24/2021 DR WAF JUNE 2021 29
Drug interactions
• Complexation with metallic ions (Fe, Al, Mg, Ca & Zn) - Common to
all fluoroquinolones. - Chelation complexes provides the basis for
their incompatibilities with antacids, hematinics, and mineral
supplements containing divalent or trivalent metals
• CYP1A2 inhibition: increase the levels of theophylline, warfarin &
caffeine; especially by ciprofloxacin & pefloxacin ( Lomefloxacin,
Levofloxacin & Sparfloxacin have no effect )
• NSAIDS: increase CNS toxicity of FQs; seizures may occur
• FQs which prolong QTs interval should be used with caution those
receiving class 1A, class III antiarrhythmic; erythromycin, TCAs etc.
8/24/2021 DR WAF JUNE 2021 30
Contraindications & precautions
• Patients with seizures
• Pregnancy & lactation
• Children below 18 years
• Drugs prolonging QT interval are contraindicated in patients of
cardiac arrhythmia & in hypokalemia
• Hepatic & renal failure
8/24/2021 DR WAF JUNE 2021 31
• THANK YOU.
8/24/2021 DR WAF JUNE 2021 32

More Related Content

What's hot

Cephalosporins
Cephalosporins Cephalosporins
Cephalosporins
Naser Tadvi
 
Sulphonamides Pharmacology For Pharmacy students
Sulphonamides Pharmacology For Pharmacy studentsSulphonamides Pharmacology For Pharmacy students
Sulphonamides Pharmacology For Pharmacy students
Malay Pandya
 
Antifungal agents
Antifungal agentsAntifungal agents
Antifungal agents
tatti09876
 
Antiviral drugs final
Antiviral drugs finalAntiviral drugs final
Antiviral drugs final
Deepa Devkota
 
Antimicrobial 3 protein synthesis inhibitors
Antimicrobial 3 protein synthesis inhibitorsAntimicrobial 3 protein synthesis inhibitors
Antimicrobial 3 protein synthesis inhibitors
Aseenat Mansour
 
Cephalosporins Pharmacology
Cephalosporins PharmacologyCephalosporins Pharmacology
Cephalosporins Pharmacology
Koppala RVS Chaitanya
 
Quinolones.pptx
Quinolones.pptxQuinolones.pptx
Quinolones.pptx
Subramani Parasuraman
 
Pharmacology - Quinolones ,Folic Acids Antagonist ,and urinary tract Antiseptics
Pharmacology - Quinolones ,Folic Acids Antagonist ,and urinary tract AntisepticsPharmacology - Quinolones ,Folic Acids Antagonist ,and urinary tract Antiseptics
Pharmacology - Quinolones ,Folic Acids Antagonist ,and urinary tract Antiseptics
Areej Abu Hanieh
 
Quinolones fluoroquinolones Pharmacology
Quinolones fluoroquinolones PharmacologyQuinolones fluoroquinolones Pharmacology
Quinolones fluoroquinolones Pharmacology
Koppala RVS Chaitanya
 
Antiviral drugs
Antiviral drugsAntiviral drugs
Antiviral drugs
MirzaAnwarBaig1
 
Quinolones and fluoroquinolones
Quinolones and fluoroquinolonesQuinolones and fluoroquinolones
Quinolones and fluoroquinolones
Koppala RVS Chaitanya
 
Introduction to antifungal drugs
Introduction to antifungal drugsIntroduction to antifungal drugs
Introduction to antifungal drugs
Subramani Parasuraman
 
Aminoglycosides
AminoglycosidesAminoglycosides
Aminoglycosides
kencha swathi
 
Macrolide antibiotics
Macrolide antibioticsMacrolide antibiotics
Macrolide antibiotics
bibi umeza
 
Sulfonamides and cotrimoxazole - drdhriti
Sulfonamides and cotrimoxazole - drdhritiSulfonamides and cotrimoxazole - drdhriti
Sulfonamides and cotrimoxazole - drdhriti
http://neigrihms.gov.in/
 
Fluroquinolones 2
Fluroquinolones 2Fluroquinolones 2
Fluroquinolones 2VIJAI KUMAR
 
sulfoamide
sulfoamidesulfoamide
Macrolide Antibiotics
Macrolide AntibioticsMacrolide Antibiotics
Macrolide Antibiotics
ANUSHA SHAJI
 
AntiViral drug
AntiViral drugAntiViral drug
AntiViral drug
Sumit Kumar
 

What's hot (20)

Cephalosporins
Cephalosporins Cephalosporins
Cephalosporins
 
Sulphonamides Pharmacology For Pharmacy students
Sulphonamides Pharmacology For Pharmacy studentsSulphonamides Pharmacology For Pharmacy students
Sulphonamides Pharmacology For Pharmacy students
 
Antifungal agents
Antifungal agentsAntifungal agents
Antifungal agents
 
Antiviral drugs final
Antiviral drugs finalAntiviral drugs final
Antiviral drugs final
 
Antimicrobial 3 protein synthesis inhibitors
Antimicrobial 3 protein synthesis inhibitorsAntimicrobial 3 protein synthesis inhibitors
Antimicrobial 3 protein synthesis inhibitors
 
Aminoglycosides
AminoglycosidesAminoglycosides
Aminoglycosides
 
Cephalosporins Pharmacology
Cephalosporins PharmacologyCephalosporins Pharmacology
Cephalosporins Pharmacology
 
Quinolones.pptx
Quinolones.pptxQuinolones.pptx
Quinolones.pptx
 
Pharmacology - Quinolones ,Folic Acids Antagonist ,and urinary tract Antiseptics
Pharmacology - Quinolones ,Folic Acids Antagonist ,and urinary tract AntisepticsPharmacology - Quinolones ,Folic Acids Antagonist ,and urinary tract Antiseptics
Pharmacology - Quinolones ,Folic Acids Antagonist ,and urinary tract Antiseptics
 
Quinolones fluoroquinolones Pharmacology
Quinolones fluoroquinolones PharmacologyQuinolones fluoroquinolones Pharmacology
Quinolones fluoroquinolones Pharmacology
 
Antiviral drugs
Antiviral drugsAntiviral drugs
Antiviral drugs
 
Quinolones and fluoroquinolones
Quinolones and fluoroquinolonesQuinolones and fluoroquinolones
Quinolones and fluoroquinolones
 
Introduction to antifungal drugs
Introduction to antifungal drugsIntroduction to antifungal drugs
Introduction to antifungal drugs
 
Aminoglycosides
AminoglycosidesAminoglycosides
Aminoglycosides
 
Macrolide antibiotics
Macrolide antibioticsMacrolide antibiotics
Macrolide antibiotics
 
Sulfonamides and cotrimoxazole - drdhriti
Sulfonamides and cotrimoxazole - drdhritiSulfonamides and cotrimoxazole - drdhriti
Sulfonamides and cotrimoxazole - drdhriti
 
Fluroquinolones 2
Fluroquinolones 2Fluroquinolones 2
Fluroquinolones 2
 
sulfoamide
sulfoamidesulfoamide
sulfoamide
 
Macrolide Antibiotics
Macrolide AntibioticsMacrolide Antibiotics
Macrolide Antibiotics
 
AntiViral drug
AntiViral drugAntiViral drug
AntiViral drug
 

Similar to Quinolones and flouroquinolones

Fluroquinolones 01 01-19
Fluroquinolones 01 01-19Fluroquinolones 01 01-19
Fluroquinolones 01 01-19
uma advani
 
Quinolones and fluroquinolones
Quinolones and fluroquinolonesQuinolones and fluroquinolones
Quinolones and fluroquinolones
zeelmevada
 
Quinolones and FLUOROQUINOLONES
Quinolones and FLUOROQUINOLONESQuinolones and FLUOROQUINOLONES
Quinolones and FLUOROQUINOLONES
ISF COLLEGE OF PHARMACY MOGA
 
QUINOLONES.pptx
QUINOLONES.pptxQUINOLONES.pptx
QUINOLONES.pptx
Mayurjaganiya1
 
Quinolones
QuinolonesQuinolones
Quinolones
Shubham Marbade
 
3.ppt
3.ppt3.ppt
3 (1).ppt, Quinolones, Antibiotcs, Pharmacology
3 (1).ppt, Quinolones, Antibiotcs, Pharmacology3 (1).ppt, Quinolones, Antibiotcs, Pharmacology
3 (1).ppt, Quinolones, Antibiotcs, Pharmacology
MaggieAlex1
 
FLUOROQUINOLONES.pptx
FLUOROQUINOLONES.pptxFLUOROQUINOLONES.pptx
FLUOROQUINOLONES.pptx
SumeetDumbre
 
quinolones-160305015356-converted.pptx
quinolones-160305015356-converted.pptxquinolones-160305015356-converted.pptx
quinolones-160305015356-converted.pptx
alaguprakash2
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
SHARIQUE RAZA
 
Quinolones
QuinolonesQuinolones
Quinolones
Medhat Saleh
 
Quinolones | drug develoupment | mechanism of action | future
Quinolones | drug develoupment | mechanism of action | futureQuinolones | drug develoupment | mechanism of action | future
Quinolones | drug develoupment | mechanism of action | future
Arun Geetha Viswanathan
 
AMA-_Fluoroqinolones.pdf
AMA-_Fluoroqinolones.pdfAMA-_Fluoroqinolones.pdf
AMA-_Fluoroqinolones.pdf
SanjayaManiDixit
 
Pharmacology of Anti- Tubercular Drugs
Pharmacology of Anti- Tubercular DrugsPharmacology of Anti- Tubercular Drugs
Pharmacology of Anti- Tubercular Drugs
Nem kumar Jain
 
Quinolone & Fluoroquinolones
 Quinolone & Fluoroquinolones Quinolone & Fluoroquinolones
Quinolone & Fluoroquinolones
Manoj Kumar
 
Quinolone
QuinoloneQuinolone
Quinolone
PriyankaBhatta3
 
chinna 21102.pptx
chinna 21102.pptxchinna 21102.pptx
chinna 21102.pptx
PriyankaNidumolu
 
Antifungal agents
Antifungal agentsAntifungal agents
Antifungal agents
Koppala RVS Chaitanya
 

Similar to Quinolones and flouroquinolones (20)

Fluroquinolones 01 01-19
Fluroquinolones 01 01-19Fluroquinolones 01 01-19
Fluroquinolones 01 01-19
 
Quinolones and fluroquinolones
Quinolones and fluroquinolonesQuinolones and fluroquinolones
Quinolones and fluroquinolones
 
Quinolones and FLUOROQUINOLONES
Quinolones and FLUOROQUINOLONESQuinolones and FLUOROQUINOLONES
Quinolones and FLUOROQUINOLONES
 
QUINOLONES.pptx
QUINOLONES.pptxQUINOLONES.pptx
QUINOLONES.pptx
 
Quinolones
QuinolonesQuinolones
Quinolones
 
3.ppt
3.ppt3.ppt
3.ppt
 
3 (1).ppt, Quinolones, Antibiotcs, Pharmacology
3 (1).ppt, Quinolones, Antibiotcs, Pharmacology3 (1).ppt, Quinolones, Antibiotcs, Pharmacology
3 (1).ppt, Quinolones, Antibiotcs, Pharmacology
 
3.ppt
3.ppt3.ppt
3.ppt
 
FLUOROQUINOLONES.pptx
FLUOROQUINOLONES.pptxFLUOROQUINOLONES.pptx
FLUOROQUINOLONES.pptx
 
quinolones-160305015356-converted.pptx
quinolones-160305015356-converted.pptxquinolones-160305015356-converted.pptx
quinolones-160305015356-converted.pptx
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
Quinolones
QuinolonesQuinolones
Quinolones
 
Quinolones | drug develoupment | mechanism of action | future
Quinolones | drug develoupment | mechanism of action | futureQuinolones | drug develoupment | mechanism of action | future
Quinolones | drug develoupment | mechanism of action | future
 
AMA-_Fluoroqinolones.pdf
AMA-_Fluoroqinolones.pdfAMA-_Fluoroqinolones.pdf
AMA-_Fluoroqinolones.pdf
 
Quinolones &UTI
Quinolones &UTIQuinolones &UTI
Quinolones &UTI
 
Pharmacology of Anti- Tubercular Drugs
Pharmacology of Anti- Tubercular DrugsPharmacology of Anti- Tubercular Drugs
Pharmacology of Anti- Tubercular Drugs
 
Quinolone & Fluoroquinolones
 Quinolone & Fluoroquinolones Quinolone & Fluoroquinolones
Quinolone & Fluoroquinolones
 
Quinolone
QuinoloneQuinolone
Quinolone
 
chinna 21102.pptx
chinna 21102.pptxchinna 21102.pptx
chinna 21102.pptx
 
Antifungal agents
Antifungal agentsAntifungal agents
Antifungal agents
 

Recently uploaded

Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
Rohit chaurpagar
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
MedicoseAcademics
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
SumeraAhmad5
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
DrSathishMS1
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
Sujoy Dasgupta
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
MedicoseAcademics
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
Catherine Liao
 

Recently uploaded (20)

Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
 

Quinolones and flouroquinolones

  • 1. QUINOLONES AND FLOUROQUINOLONES DR LINUS WAFULA,JKUAT. JUNE 2021.
  • 2. QUINOLONES AND FLOUROQUINOLONES • Introduction • A group of synthetic antibacterial agents mainly effective against gram negative organisms • Nalidixic acid first member introduced in 1964 for urinary and GIT infections • Synthetic fluorinated analogs of nalidixic acid: are fluoroquinolones (FQs) with extended spectrum and systemic effects in 1980s. • FQs are BACTERICIDAL, act by interfering with DNA replication. Since then many synthesized with useful spectrum. 8/24/2021 DR WAF JUNE 2021 2
  • 3. Nalidixic acid • The first quinolone, nalidixic acid, was isolated as a by-product of the synthesis of chloroquine • Less potent ,limited spectrum Active against gram negative bacteria – E.coli, Proteus, Klebsiella, Enterobacter, Shigella • Inhibits bacterial DNA gyrase, Bactericidal Resistance develops rapidly • Pharmacokinetics: Absorbed orally Metabolized in liver, highly protein bound, excreted in urine, half life – 8 hrs. • Concentration in urine is lethal to common urinary pathogens (20 – 50 times that in plasma) Quinolones 8/24/2021 DR WAF JUNE 2021 3
  • 4. • Nalidixic acid Adverse effects : • GI upset, rashes Neurological toxicity (in children) – headache, vertigo, drowsiness, visual disturbances, seizures • Hemolysis in G6PD deficiency • Indication: • Urinary antiseptic • Diarrhoea caused by E.coli, Proteus, Shigella, Salmonella Ampicillin resistant Shigella enteritis (cont..,) Quinolones 8/24/2021 DR WAF JUNE 2021 4
  • 5. QUINOLONES. • 2 Quinolones are synthetic antimicrobials having a quinolone structure. • Active against gram-ve bacteria, newer fluorinated compounds also inhibit gram +ve bacteria. • • First member was nalidixic acid introduced in 1960’s • • Their usefulness is limited to urinary and GI tract infections because of • Low potency • Modest blood and tissue levels • Limited spectrum • High frequency of bacterial resistance 8/24/2021 DR WAF JUNE 2021 5
  • 6. 8/24/2021 DR WAF JUNE 2021 6
  • 7. MODE OF ACTION. In gram negative bacteria – Inhibition of DNA gyrase enzyme (Inhibit negative super coiling) In gram positive bacteria – •Inhibition of Topoisomerase IV – Inhibition of nicking and separation of daughter DNA strands after DNA replication •The malformed DNA is digested by Exoneucleases Mechanism of Action 8/24/2021 DR WAF JUNE 2021 7
  • 8. 8/24/2021 DR WAF JUNE 2021 8
  • 9. Mechanism of action. • DNA- Enzyme- . The gyrase is composed of two A subunits and two B subunits. • The A subunits can cut one of double strands of the DNA • .This is an ATP- dependent reaction. The energy is provided by B units. • . FQs are inhibitor of A subunits. • Therefore, the action of gyrase is inhibited and DNA replication or transcription is blocked as result of the death of bacteria. 8/24/2021 DR WAF JUNE 2021 9
  • 10. 8/24/2021 DR WAF JUNE 2021 10
  • 11. Mechanism of Resistance to Quinolones & FQ. • Due to • 1. a) One or more point mutations in the quinolone binding region of the target enzyme b) A change in the permeability of the organism 2. DNA gyrase is the primary target in E coli, with single-step mutants exhibiting amino acid substitution in the A subunit of gyrase 3.Topoisomerase Ⅳ is a secondary target in E coli that is altered in mutants expressing higher levels of resistance. 8/24/2021 DR WAF JUNE 2021 11
  • 12. 4.In staphylococci and streptococci, the situation is reversed, topoisomerase Ⅳ is the primary target, and gyrase is the secondary target. 5.Resistance to one fluoroquinolone, particularly if of high level, generally confers cross-resistance to all other members of this class. 8/24/2021 DR WAF JUNE 2021 12
  • 13. General features of FQs • Rapidly bactericidal & high potency • Long post antibiotic effect on pseudomonas & enterobacteriaceae Attain high levels in body fluids & tissues • Diarrhea and antibiotic-associated colitis unusual • Low frequency of mutational resistance Active against many β-lactam & aminoglycoside resistant bacteria Less active at acidic pH 8/24/2021 DR WAF JUNE 2021 13
  • 14. Classification of FQs First generation. 1. Introduced in 1980 with one fluoro substitution Norfloxacin Ciprofloxacin Ofloxacin (only as ophthalmic in the United States) Pefloxacin 2. Second-generation: In 1990s with additional fluoro & other substitution extending antimicrobial spectrum to gram positive bacteria ,anaerobes and longer half life. 3.Levofloxacin, Moxifloxacin, Gemifloxacin, Prulifloxacin, Lomefloxacin, Sparfloxacin, Finafloxacin . 8/24/2021 DR WAF JUNE 2021 14
  • 15. 8/24/2021 DR WAF JUNE 2021 15
  • 16. Pharmacokinetics of FQs: • Prototype : Ciprofloxacin • Oral given, well absorbed, be impaired by divalent cations, including those in antacid • Distributed widely in body fluids and tissues but CSF & aqueous levels are low • Urinary & billiary concentrations are 10-50 fold higher than plasma • Less active in acidic pH • Pass placenta reach to the fetus, • Biotransformation of the drugs in the liver • Most eliminated by renal, either tubular secretion or glomerular filtration. 8/24/2021 DR WAF JUNE 2021 16
  • 17. Therapeutic applications of FQs. • Fluoroquinolones are extensively used treating general infection. • a. Urinary tract infections, even when caused by multidrug- resistant bacteria: cystitis, prostatitis,pyelonephritis. • b. Intestinal and biliary tract infections • c. skin and Soft tissue infections, infected skin ulcers and burns. • d. Bone, joint and intra-abdominal infections • e. Respiratory tract infections: empyema, pneumonia, lung abcess. 8/24/2021 DR WAF JUNE 2021 17
  • 18. Uses • Bacterial Meningitis • Enteric fever, caused by Salmonelle spp • Bacterial Diarrhoeal diseases caused by campylobacter, shigella • Gonorrhea and chancroid • Conjuctivitis • Tuberculosis 8/24/2021 DR WAF JUNE 2021 18
  • 19. CIPROFLOXACIN • prototype): Highly effective against pseudomonas • • Drug of choice for prophylaxis & treatment of Anthrax & prophylaxis of meningococcal meningitis. • Typhoid • UTIs • Bacterial gastroenteritis • Osteomyelitis & joint infections • Gonorrhea & chanchroid • Septicemia due to gram negative organisms • • Respiratory infections especially due to Mycoplasma, H. influenza, Legionella • Prophylaxis of infections in neutropenic & cancer patients • • Topical use: conjunctivitis Unique features of different FQs. 8/24/2021 DR WAF JUNE 2021 19
  • 20. NORFLOXACIN • Minimum oral bioavailability • • Minimum Inhibitory concentration for gram negative bacteria is 8-10 times higher than that of ciprofloxacin. • Attains lower concentration in tissues Less potent than ciprofloxacin Primarily used in urinary & genital tract infections For bacterial diarrheas it is good as anaerobic flora of the gut not affected. Unique features of different FQs. 8/24/2021 DR WAF JUNE 2021 20
  • 21. Unique features of different FQs PEFLOXACIN: • Methyl derivative of Norfloxacin Completely absorbed, exhibits cumulation on repeated absorbtion • More lipid soluble, CSF concentration are higher than other FQs • Highly metabolized in liver to active metabolite • Dose needs to be reduced in liver disease but not in renal insufficiency • Preferred for meningeal infections • 200,400mg tablet available & injection 400mg/5ml to be used diluted in glucose solution but not in saline as it precipitates in presence of Chloride ions. 8/24/2021 DR WAF JUNE 2021 21
  • 22. Unique features of different FQs OFLOXACIN: • Lipid soluble oral bioavailability is high • Food does not interfere its absorption Oral tablet (200 & 400mg) & i.v.(200mg) Largely excreted unchanged by kidney ,so dose need reduced in renal failure Effective for gonococcal infection, including disseminated disease. • Occasionally used for treatment of tuberculosis and atypical mycobacterial infections • Suitable for eradication of meningococcal infections from carriers. • Highly effective in: leprosy, Chlamydial urethritis or cervicitis , atypical (Mycoplasma) pneumonia & Chronic bronchitis (cont..,) 8/24/2021 DR WAF JUNE 2021 22
  • 23. SPARFLOXACIN. • Excreted by both renal & hepatic Long half life • Increased action against gram positive bacteria, Streptococcus, Staphylococcus, Enterococcus,Anaerobes & mycobacteria • NOT effective against Peudomonas • Indication: upper and lower respiratory tract infections. Highly effective in Tuberculosis, , Macobacterium Avium Complex, Leprosy • Adverse effects: Phototoxic QT prolongation (cont..,) 8/24/2021 DR WAF JUNE 2021 23
  • 24. MOXIFLOXACIN • Hepatic metabolism & biliary excretion Tablet & intravenous (400 mg) Indications: MDR tuberculosis, Bronchitis, pneumonia, otitis media, Urinary concentrations are low not suitable for UTI • Contraindications : Primarily metabolised in liver, not used in liver disease Patients with Seizures & Patients receiving proarrythmic drugs as it prolong Q-T interval. 8/24/2021 DR WAF JUNE 2021 24
  • 25. LEVOFLOXACIN: • L-isomer of ofloxacin • Maximum oral bioavailablity, given orally or i.v. • Excreted unchanged by kidney Indications : • Upper and lower respiratory tract infections. Community acquired pneumonia : • (Respiratory FQ) MDR TB, nosocomial infections Eye drops for bacterial conjunctivitis & corneal ulcer. (cont..,) 8/24/2021 DR WAF JUNE 2021 25
  • 26. LOMEFLOXACIN • Similar to Ciprofloxacin ,more active against Gram negative bacilli & chlamydia Longer plasma half life ,once daily administration 400 mg tablet available & Topical eye drops available (0.3%) Side effect: • Photo toxicity & Q-T prolongation Withdrawn in USA & other countries, available in India (cont..,) 8/24/2021 DR WAF JUNE 2021 26
  • 27. 8/24/2021 DR WAF JUNE 2021 27
  • 28. WITHDRAWN FROM THE MARKET • Due to adverse effects like • Gatifloxacin: QT prolongation & dysglycemia (increase or decrease blood sugar level: risky in diabetics) withdrawn from market. • Temafloxacin: immune hemolytic anemia • Grepafloxacin: cardiotoxicity: QT prolongation • Clinafloxacin : phototoxicity 8/24/2021 DR WAF JUNE 2021 28
  • 29. SIDE EFFECTS. • The most common effects are • a) nausea, vomiting, and diarrhea. • b) Headache, dizziness, insomnia, skin rash, occasionally. • c). Photosensitivity occurs with lomefloxacin and pefloxacin. • d). FQs may damage growing cartilage and cause an arthropathy. • They are not used in patients under 18years of age. • The arthropathy is reversible. • e) FDA has issued warning regarding peripheral neuropathy • f) Ciprofloxacin prophylaxis use in anthrax patients associated with damage to muscle ligament. 8/24/2021 DR WAF JUNE 2021 29
  • 30. Drug interactions • Complexation with metallic ions (Fe, Al, Mg, Ca & Zn) - Common to all fluoroquinolones. - Chelation complexes provides the basis for their incompatibilities with antacids, hematinics, and mineral supplements containing divalent or trivalent metals • CYP1A2 inhibition: increase the levels of theophylline, warfarin & caffeine; especially by ciprofloxacin & pefloxacin ( Lomefloxacin, Levofloxacin & Sparfloxacin have no effect ) • NSAIDS: increase CNS toxicity of FQs; seizures may occur • FQs which prolong QTs interval should be used with caution those receiving class 1A, class III antiarrhythmic; erythromycin, TCAs etc. 8/24/2021 DR WAF JUNE 2021 30
  • 31. Contraindications & precautions • Patients with seizures • Pregnancy & lactation • Children below 18 years • Drugs prolonging QT interval are contraindicated in patients of cardiac arrhythmia & in hypokalemia • Hepatic & renal failure 8/24/2021 DR WAF JUNE 2021 31
  • 32. • THANK YOU. 8/24/2021 DR WAF JUNE 2021 32